Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Combo therapy for melanoma gets priority review

Written by: | no-reply@reuters.com | Dated: Friday, December 22nd, 2017

 

Novartis combo therapy for melanoma gets FDA priority review

 

The U.S. Food and Drug Administration has granted priority review for Novartis’s Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said on Friday.

The review covers the combination therapy for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations following complete resection.

In October, the FDA also granted breakthrough therapy designation to Tafinlar in combination with Mekinist for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection, the company said in a statement.

 

(Reporting by Michael Shields; Editing by Vyas Mohan)

 

Reuters source:

https://www.reuters.com/article/us-novartis-melanoma/novartis-combo-therapy-for-melanoma-gets-fda-priority-review-idUSKBN1EG0J9

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom